![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JM Herbert, A Bernat, F Dol, JP Herault, B Crepon and JC Lormeau
Haemobiology Research Department, Sanofi Recherche, Toulouse, France.
DX 9065A is the first member of a newly developed series of synthetic and selective inhibitors of factor Xa. DX 9065A inhibited in a dose- dependent manner human factor Xa with K iota value of 3.1 +/- 0.5 nM. Steady-state studies revealed that DX 9065A was a competitive inhibitor of factor Xa. DX 9065A inhibited thrombin generation occurring via both the extrinsic and intrinsic pathway in vitro and in vivo. After i.v. injection to rabbits, DX 9065A displayed prolonged anti-factor Xa activity and inhibition of thrombin generation. Pretreatment of mice with DX 9065A dose-dependently improved the survival rate of mice injected with a lethal dose of tissue factor (ED50 = 1.1 +/- 0.2 mg/kg). After p.o. administration, DX 9065A caused a reduction in tissue factor-induced mortality of mice with ED50 value of 56 +/- 7 mg/kg. When given i.v. to rats, DX 9065A exhibited a dose-dependent antithrombotic effect against factor Xa + stasis-induced venous thrombosis (ED50 = 1.2 +/- 0.7 mg/kg i.v.), but also in an arteriovenous shunt thrombosis model (ED50 = 8.1 +/- 3.5 mg/kg i.v.) without affecting bleeding time significantly. Similar effects were obtained after s.c. or p.o. administration. In rabbits, after i.v., s.c. or p.o. administration, DX 9065A inhibited stasis-induced thrombosis after injection of tissue factor with ED50 values of 0.03 +/- 0.01, 0.3 +/- 0.07 and 50.5 +/- 19 mg/kg, respectively (n = 10). DX 9065A inhibited in a dose-dependent manner endotoxin-induced venous thrombosis in the rabbit (ED50 = 0.25 +/- 0.1 mg/kg i.v.) (n = 5) and reduced the decrease in platelet number and circulating fibrinogen levels in an experimental model of tissue factor-induced disseminated intravascular coagulation. Compared to standard heparin, DX 9065A exhibited a favorable antithrombotic/bleeding ratio, therefore showing that it might be considered as a promising compound in the treatment and prevention of various thrombotic diseases.
This article has been cited by other articles:
|
|
 |
|
  J. I. Weitz, J. Hirsh, and M. M. Samama New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 234S - 256S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A Nutescu and A. K Wittkowsky Direct Thrombin Inhibitors for Anticoagulation Ann. Pharmacother., January 1, 2004; 38(1): 99 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates and J. I. Weitz Emerging Anticoagulant Drugs Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1491 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorrain, L. Millet, I. Lechaire, S. Lochot, P. Ferrari, C. Visconte, M. Sainte-Marie, C. Lunven, C. N. Berry, P. Schaeffer, et al. Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin Inhibitor J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 567 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Wong, E. J. Crain, C. A. Watson, A. M. Zaspel, M. R. Wright, P. Y. Lam, D. J. P. Pinto, R. R. Wexler, and R. M. Knabb Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 993 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Dyke, R. C. Becker, N. S. Kleiman, J. S. Hochman, E. G. Bovill, A. M. Lincoff, G. Gerstenblith, V. Dzavik, L. H. Gardner, V. Hasselblad, et al. First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation Circulation, May 21, 2002; 105(20): 2385 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz and J. Hirsh New Anticoagulant Drugs Chest, January 1, 2001; 119(1_suppl): 95S - 107S. [Full Text] [PDF]
|
|
|
|
|
|
F. Bono, P. Schaeffer, J.-P. Herault, C. Michaux, A.-L. Nestor, J.-C. Guillemot, and J.-M. Herbert Factor Xa Activates Endothelial Cells by a Receptor Cascade Between EPR-1 and PAR-2 Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20 (11): e107 - e112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Ansell, J. I. Weitz, and A. J. Comerota Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism Hematology, January 1, 2000; 2000(1): 266 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kamata, H. Kawamoto, T. Honma, T. Iwama, and S.-H. Kim Structural basis for chemical inhibition of human blood coagulation factor Xa PNAS, June 9, 1998; 95(12): 6630 - 6635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Hérault, A. Bernat, A. M. Pflieger, J. C. Lormeau, and J. M. Herbert Comparative Effects of Two Direct and Indirect Factor Xa Inhibitors on Free and Clot-Bound Prothrombinase J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 16 - 22. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
